The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-lectin Sandwich Arrays
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
Changes to the glycan structures of proteins secreted by cancer cells are known to be functionally important and to have potential diagnostic value. However, an exploration of the population variation and prevalence of glycan alterations on specific proteins has been lacking because of limitations in conventional glycobiology methods. Here we report the use of a previously developed antibody-lectin sandwich array method to characterize both the protein and glycan levels of specific mucins and carcinoembryonic antigen-related proteins captured from the sera of pancreatic cancer patients (n = 23) and control subjects (n = 23). The MUC16 protein was frequently elevated in the cancer patients (65% of the patients) but showed no glycan alterations, whereas the MUC1 and MUC5AC proteins were less frequently elevated (30 and 35%, respectively) and showed highly prevalent (up to 65%) and distinct glycan alterations. The most frequent glycan elevations involved the Thomsen-Friedenreich antigen, fucose, and Lewis antigens. An unexpected increase in the exposure of alpha-linked mannose also was observed on MUC1 and MUC5ac, indicating possible N-glycan modifications. Because glycan alterations occurred independently from the protein levels, improved identification of the cancer samples was achieved using glycan measurements on specific proteins relative to using the core protein measurements. The most significant elevation was the cancer antigen 19-9 on MUC1, occurring in 19 of 23 (87%) of the cancer patients and one of 23 (4%) of the control subjects. This work gives insight into the prevalence and protein carriers of glycan alterations in pancreatic cancer and points to the potential of using glycan measurements on specific proteins for highly effective biomarkers.
Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.
Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P Int J Biol Sci. 2025; 21(1):63-74.
PMID: 39744438 PMC: 11667816. DOI: 10.7150/ijbs.101861.
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance.
Hollander E, Flock R, McDevitt J, Vostrejs W, Campbell S, Orlen M JCI Insight. 2024; 9(12).
PMID: 38912584 PMC: 11383181. DOI: 10.1172/jci.insight.178804.
Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.
Silva M Explor Target Antitumor Ther. 2023; 4(3):366-395.
PMID: 37455827 PMC: 10344901. DOI: 10.37349/etat.2023.00140.
Bueno-Sanchez J, Gomez-Gutierrez A, Maldonado-Estrada J, Quintana-Castillo J Front Endocrinol (Lausanne). 2023; 14:1087845.
PMID: 37206444 PMC: 10190602. DOI: 10.3389/fendo.2023.1087845.
Role of tumor cell sialylation in pancreatic cancer progression.
Marciel M, Haldar B, Hwang J, Bhalerao N, Bellis S Adv Cancer Res. 2023; 157:123-155.
PMID: 36725107 PMC: 11342334. DOI: 10.1016/bs.acr.2022.07.003.